ALCOR.PA - Biocorp Production

Paris - Paris Delayed Price. Currency in EUR
12.00
+0.10 (+0.84%)
At close: 5:05PM CEST
Stock chart is not supported by your current browser
Previous Close11.90
Open11.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range11.80 - 12.00
52 Week Range6.80 - 14.60
Volume243
Avg. Volume2,148
Market Cap49.556M
Beta (3Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.70
  • Bloomberg17 days ago

    Euro-Area's Biggest Companies Index Enters Bull Market on Trade

    (Bloomberg) -- The gauge for the euro-area’s largest listed companies closed in a bull market on Wednesday, extending a rally fueled by the trade truce between the U.S. and China as well as by bets on softer monetary policy.The Euro Stoxx 50 Index gained 0.9% by the close, up about 20% from a late-December low. Equities in the region, led by the tech sector, are getting a boost from the decision by the U.S. and China to resume trade talks. Utilities stocks have also rallied recently amid falling bond yields.An added boost to sentiment is softer rhetoric from global central banks, which last month signaled openness to rate cuts and further stimulus. In the past 24 hours, Christine Lagarde was nominated to take the helm of the European Central Bank later this year, ushering in a candidate whom analysts anticipate will take up departing President Mario Draghi’s mantle in providing stimulus.“The key driving force behind the recent rally has been the unexpected decision by Draghi to announce much greater central bank support than many investors had expected,” said Andrew Milligan, head of global strategy at Aberdeen Standard Investments in Edinburgh. “Looking ahead, we need to see market expectations of easier central bank policy matched by continued good news from the politicians on trade -- or investor sentiment will turn again.”Aberdeen is overweight global equities, but neutral on European stocks because of political risk premia.Some of Wednesday’s biggest advancers included Anheuser-Busch InBev NV, which rose 4.1% after a sale of shares in its Asia Pacific beer unit was priced at the high end of the range. Sanofi added 1.5% after Biocorp said it’s in exclusive talks about introducing its Mallya connected device into the company’s integrated diabetes care platform.“While the European economy remains slow growing with the important manufacturing sector still suffering from a modest recession as global trade stagnates, there are many multinational companies in Europe with solid global operations,” Milligan said.To contact the reporter on this story: Ksenia Galouchko in London at kgalouchko1@bloomberg.netTo contact the editors responsible for this story: Blaise Robinson at brobinson58@bloomberg.net, Paul Jarvis, Jon MenonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Business Wire17 days ago

    BIOCORP Enters Exclusive Negotiations With SANOFI to Use Their MallyaTM Connected Device With Sanofi’s Integrated Diabetes Care Platform

    BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (ALCOR.PA), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces that they have entered into an exclusive negotiation with SANOFI, a worldwide leader within the pharmaceutical industry, aimed at introducing their Mallya connected device into SANOFI's integrated diabetes care platform.

  • Did Biocorp Production's (EPA:ALCOR) Share Price Deserve to Gain 37%?
    Simply Wall St.last month

    Did Biocorp Production's (EPA:ALCOR) Share Price Deserve to Gain 37%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

  • Business Wirelast month

    BIOCORP Announces The CE IIb Approval of Its Mallya Device

    BIOCORP (ALCOR.PA) (FR0012788065 – ALCOR / PEA‐PME eligible), French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, today announces that Mallya has obtained the CE 0459 mark as medical device class IIb. Mallya is a smart sensor that turns conventional insulin pens into connected devices. Mallya records the key treatment information (selected dose, date and time of injection) and sends it to a dedicated mobile application.